Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Leah H. Biller

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7386-7121; OpenAlex author ID A5071684616. Sources: OpenAlex.

Their work

Papers
7 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
52
Papers, trials and grants by year

2021: 2 papers · 2022: none · 2023: 2 papers · 2024: 1 paper · 2025: 1 paper · 2026: 1 paper

Papers 7

  1. A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2. Co-author DOI 10.1158/1078-0432.ccr-24-3766↗
  2. Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreat… Co-author DOI 10.1200/po-25-00332↗
  3. Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the T… Co-author DOI 10.1158/2326-6066.cir-23-1073↗
  4. Adipose tissue and skeletal muscle wasting precede clinical diagnosis of pancreatic cancer. Co-author DOI 10.1038/s41467-023-40024-3↗
  5. A Phase I Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-dose Gemcitabine in Patients with Metastatic Pancr… Co-author DOI 10.1158/1078-0432.ccr-23-2005↗
  6. Inherited Pancreatic Cancer Syndromes and High-Risk Screening. Co-author DOI 10.1016/j.soc.2021.06.002↗
  7. Safety and efficacy of combination chemotherapy regimens in older adults with pancreatic ductal adenocarcinoma: a systematic review. First author DOI 10.21037/jgo-21-87↗

Closest collaborators

The 25 strongest of 52 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Brian Matthew Wolpin · 6 shared papers, 2021–2026 · strength 0.96
  2. Matthew B.B. Yurgelun · 4 shared papers, 2023–2026 · strength 0.61
  3. Jonathan Andrew Nowak · 4 shared papers, 2023–2026 · strength 0.61
  4. Harshabad Singh · 4 shared papers, 2023–2026 · strength 0.60
  5. Douglas Adam Rubinson · 4 shared papers, 2023–2026 · strength 0.60
  6. Brandon M. Huffman · 4 shared papers, 2023–2026 · strength 0.60
  7. Kimberly J. Perez · 4 shared papers, 2023–2026 · strength 0.60
  8. James M. Cleary · 4 shared papers, 2023–2026 · strength 0.60
  9. Kimmie Ng · 4 shared papers, 2023–2026 · strength 0.60
  10. Andrew J. Aguirre · 4 shared papers, 2023–2026 · strength 0.60
  11. Andrea J. Bullock · 3 shared papers, 2021–2026 · strength 0.56
  12. Srivatsan Raghavan · 3 shared papers, 2023–2026 · strength 0.47
  13. Thomas Adam Abrams · 3 shared papers, 2023–2025 · strength 0.42
  14. Mary Linton B. Peters · 2 shared papers, 2025–2026 · strength 0.34
  15. ANDREA C Enzinger · 2 shared papers, 2025–2026 · strength 0.34
  16. Alan D. D’Andrea · 2 shared papers, 2023–2026 · strength 0.31
  17. Geoffrey Ira Shapiro · 2 shared papers, 2023–2026 · strength 0.31
  18. Rishi Surana · 2 shared papers, 2024–2025 · strength 0.29
  19. Patricia Saade-Lemus · 1 shared paper, 2021 · strength 0.22
  20. Michael Goggins · 1 shared paper, 2021 · strength 0.22
  21. Nadine A. Jackson · 1 shared paper, 2026 · strength 0.19
  22. Hanna Kelly Sanoff · 1 shared paper, 2025 · strength 0.15
  23. Robert James Mayer · 1 shared paper, 2025 · strength 0.15
  24. Hannah L. Williams · 1 shared paper, 2025 · strength 0.15
  25. Kirsten L. Bryant · 1 shared paper, 2025 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.